Editor's Note: the "Trending USA Stocks" column tracks the day's top bullish stocks in the USA market, aiding investors in promptly identifying opportunities for potential gains.

18/02/2025 Eastern Time in USA The Dow Jones Industrial Average rose by 0.02%, closing at 44556.34 points; the Nasdaq Composite rose by 0.07%, closing at 20041.26 points; the S&P 500 Index rose by 0.24%, closing at 6129.58 points. Sahm has compiled the Top 10 Daily Stock Price Gainers in the USA market.

GCL Global Holdings Ltd Ordinary Shares: Overnight gain 146.0%, Merger, industry growth, and Asian expansion drive bullish sentiment and stock rally.

GCL Global Holdings Ltd, an exempted company with limited liability incorporated in the Cayman Islands on October 12, 2023, has established itself as a leading player in the Asian video game and entertainment content marketing, distribution, and publishing sector. The company, along with its group subsidiaries, has a significant presence across multiple Asian countries and regions, including Japan, Singapore, Hong Kong, Malaysia, South Korea, Taiwan, Thailand, Indonesia, and the Philippines. The firm's core business model revolves around the sale of physical and digital video games to retailers and consumers through both brick-and-mortar establishments and online channels. This diversified approach allows GCL Global Holdings to capitalize on the growing demand for interactive entertainment across various Asian markets. With its strategic positioning in the rapidly expanding Asian gaming industry, GCL Global Holdings Ltd is poised to leverage its extensive distribution network and market expertise to drive growth and capture emerging opportunities in the region's dynamic video game and entertainment content landscape.

GCL Global Holdings Ltd Ordinary Shares (GCL) has experienced a significant stock price surge due to multiple factors. The successful business combination with RF Acquisition Corp. has attracted investor attention, signaling positive growth prospects. As a leading marketer of video games and entertainment content in Asia, GCL is benefiting from the industry's rapid expansion. The company's strategic business presence across various Asian countries demonstrates strong growth potential. Year-to-date, GCL's stock has soared 177.8%, with the sustained upward trend drawing more investors and creating a positive feedback loop, further propelling the stock price. This remarkable performance underscores GCL's robust market position and investor confidence in its future prospects within the dynamic Asian gaming and entertainment sector.

GeneDx Holdings Corp Ordinary Shares - Class A: Overnight gain 47.7%, GeneDx launches innovative genomic service, reports strong sales, and forecasts optimistic growth, boosting investor confidence.

GeneDx Holdings Corp., a Delaware-incorporated entity, operates through its subsidiary Sema4, which specializes in leveraging artificial intelligence and machine learning technologies to analyze clinical and genomic data. The company's primary focus is on constructing dynamic models of human health to support personalized medicine initiatives. Through its proprietary health intelligence platform, Centrellis, GeneDx Holdings Corp. aims to provide deep insights into diseases and health conditions. This cutting-edge platform enables the company to offer scientifically-driven solutions for various medical needs, positioning itself at the forefront of data-driven healthcare advancement. The firm's mission is to revolutionize the healthcare industry by utilizing sophisticated data analytics to enhance patient outcomes and drive innovation in personalized medicine. By integrating vast amounts of clinical and genomic information, GeneDx Holdings Corp. strives to unlock new possibilities in disease prevention, diagnosis, and treatment, potentially transforming the landscape of modern healthcare delivery.

GeneDx Holdings Corp Ordinary Shares - Class A (WGS) experienced a significant stock price surge due to multiple factors. The company's introduction of the UltraRapid whole genome sequencing service, delivering results within 48 hours, showcased its technological innovation. Additionally, GeneDx's Q4 sales of $95.64 million exceeded expectations, demonstrating strong financial performance. The company's optimistic outlook for future growth, projecting annual revenue of $350-360 million by 2025, surpassed market expectations. GeneDx also anticipates at least 30% growth in its exome/genome sequencing business by 2025, with potential for adjusted net profit profitability. These factors collectively drove WGS's stock price upward, resulting in an overnight increase of 47.7% and a year-to-date gain of 46.7%.

Allogene Therapeutics: Overnight gain 39.2%, Positive clinical data boosts investor confidence in innovative cancer treatment approach

Allogene Therapeutics, Inc. (NASDAQ: ALLO) is a clinical-stage biotechnology firm specializing in the development and commercialization of allogeneic T cell therapies for cancer treatment. The company is at the forefront of immuno-oncology, focusing on engineered T cell products designed to target and eliminate cancer cells. The firm's innovative pipeline comprises "off-the-shelf" T cell product candidates, which are derived from healthy donors and can be administered to any eligible patient. This approach marks a significant departure from autologous T cell therapies, potentially offering a more scalable and efficient treatment modality. Allogene's allogeneic platform aims to overcome the limitations of current cellular therapies by providing readily available treatments that could potentially reach a broader patient population. This strategy could revolutionize cancer care by enhancing accessibility and reducing the time and cost associated with personalized therapies. As the company advances its clinical trials, investors and industry observers are closely monitoring Allogene's progress in this cutting-edge field of cancer therapeutics. The success of its allogeneic T cell therapies could represent a paradigm shift in oncology treatment, offering new hope for patients and potentially significant returns for stakeholders.

Allogene Therapeutics (ALLO) shares surged following the release of positive clinical data for Cemacabtagene Ansegedleucel in treating large B-cell lymphoma. The results validate the company's technological prowess in allogeneic T-cell therapy, bolstering investor confidence in its innovative cancer treatment approach. The substantial market potential for large B-cell lymphoma, coupled with strong capital interest in immuno-oncology, propelled ALLO's stock price up 39.2% post-announcement, with a year-to-date gain of 33.3%. The company's development of "off-the-shelf" T-cell therapies offers scalability and cost advantages over traditional methods, further enhancing its commercial prospects. This breakthrough underscores Allogene Therapeutics' (ALLO) position as a frontrunner in the rapidly evolving field of cell therapy for cancer treatment.

The Top 10 Daily Gainers in the USA market are listed as follows:

Editor's note: This content was generated by Sahm's in-house AI-enabled SaaS tool and was reviewed by our editing team.